86results about How to "Suitable for oral" patented technology

Methods for treating mesothelioma comprising administering the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) are disclosed.

The invention relates to biparatopic A-beta binding polypeptides and, more specifically, to biparatopic A-beta binding polypeptides comprising at least two immunoglobulin single variable domains binding to different epitopes of A-beta. The invention also relates to specific sequences of such polypeptides, methods of their production, and methods of using them, including methods of treatment of diseases such as Alzheimer's Disease.

The invention relates to an L-carnitine calcium fumarate and a preparation method and usages thereof. The L-carnitine calcium fumarate is characterized by oral intake, stability and no-hygroscopicity, and has stronger and more functions of nutrition and treatment, compared with corresponding internal salt and good water solubility; the preparation method is: the calcium furmarate is dissolved in the water and added with calcic alkali for reaction with the temperature increasing to 70 to 90 DEG C for 2 to 8 hours and then water is evaporated by reducing pressure. The solid obtained by drying is added into ethanol and evenly mixed, with the L-carnitine added for reaction with the temperature at 60 to 70 DEG C for 1 to 6 hours, then the mixture is put into a refrigerator for refrigeration for 2 to 8 hours and the L-carnitine calcium fumarate is finally obtained by suction and filtration; the composition containing the L-carnitine calcium fumarate can be made into one or more excipients acceptable on pharmacology, particularly solid and liquid oral intake preparation, such as powdered drug, granules, tablets, capsules, oral liquid, etc., is preferred and the solid and liquid oral intake preparation can be used for food / nutrition additives for people, or feed additives for animals, including additives for calcium supplement.

A Escherichia, Salmonella, Yersinia, Vibrio, Listeria, Shigella, or Pseudomonas bacterium that has the following components: (I) a polynucleotide encoding a heterologous antigenic determinant that induces a CTL response against a tumor cell; (II) a polynucleotide encoding a heterologous protein toxin or toxin subunit; and (III) (a) a polynucleotide encoding a transport system that expresses the products of (I) and (II) on the outer surface of the bacterium or that secretes products of (I) and (II) from the bacterium; and (IV) a polynucleotide that activates the expression of one or more of (I). (II), and / Or (III) in the bacterium wherein polynucleotides (I), (II), (III) and (IV) are different from each other and polynucleotides (I), (II) and (III) encode proteins that are different from each other.

The present invention relates to methods and compositions containing oligonucleotides suitable for administration to humans and other mammals.

The present invention relates to methods and compositions containing oligonucleotides suitable for administration to humans and other mammals.

An embodiment of the present invention relates to a compound of the general formula. The compound of formula is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Furthermore an embodiment of the present invention concerns a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.

A calcium citrate salt and its preparation method and application are disclosed. The calcium citrate salt has stronger nutritional and therapeutical effects than simple calcium citrate. The preparation method comprises the following steps: dissolving citric acid in water, adding calcium oxide or calcium hydrate or calcium carbonate, filtering to remove foreign materials after the solution is dissolved to be transparent, adding L-arginine or L-lysine or acetyl L-carnitine or propionyl l-carnitine into a filtrate, reacting at 0-100 DEG C for 2-8 h, carrying out vacuum concentration, cooling, carrying out crystallization by adding anhydrous ethanol, filtering and drying, and detecting to be qualified so as to obtain the product. A composition containing the calcium citrate salt can be made into one or more pharmacologically acceptable excipients, especially a solid-liquid oral preparation, such as pulvis, a particulate agent, a tablet, capsules and an oral liquid, etc., or directly made into a beverage, and can be used as dietary / nutritional supplement for human or a feed supplement for animals, including nutritional supplements for supplementing L-arginine, L-lysine, acetyl L-carnitine and propionyl L-carnitine.

This disclosure relates to formulations and methods of suppressing appetite and eliciting satiety (sense of being filled) in mammals through the oral administration of an effective amount of an appetite suppressing moiety.

The present invention is concerned with anticoagulants (i.e. substances that stop blood from clotting). More specifically, the present invention is concerned with orally available antithrombic oligosaccharides.

The invention discloses lactobacillus plantarum 550 with constipation relieving and sleep aiding functions and application of lactobacillus plantarum 550, belonging to the technical field of biology. The lactobacillus plantarum 550 provided by the invention is preserved in the China Center for Type Culture Collection on December 21, 2007, wherein the accession number of the lactobacillus plantarum 550 is CCTCC No. M 207202. The lactobacillus plantarum 550 provided by the invention is applied to preparation of functional food and medicines for relieving constipation, or / and helping sleep, or / and reducing cholesterol, or / and inhibiting pathogenic bacteria, or / and degrading nitrite. The lactobacillus plantarum 550 grows well and quickly on an MRS agar culture medium, is high in acid production capacity, has good gastric acid and cholate tolerance, and can be colonized in intestinal tracts. The lactobacillus plantarum 550 has a good bowel relaxing effect, strong capability of producing gamma-aminobutyric acid, the effect of reducing cholesterol in vitro, a good inhibition effect on common pathogenic bacteria, capability of rapidly degrading nitrite and the good safety.

The present invention relates to an oxopicolinamide derivative, a preparation method therefor and the pharmaceutical use thereof. In particular, the present invention relates to an oxopicolinamide derivative as shown in the general formula (AI), a preparation method therefor and a pharmaceutical composition comprising the derivative, and to the use thereof as a therapeutic agent, in particular as an inhibitor of blood coagulation factor XIa (Factor XIa, FXIa for short) and the use thereof in the preparation of a drug for treating diseases such as thromboembolism, wherein the definition of each substituent in the general formula (AI) is the same as defined in the description.

The present invention is directed to novel pharmaceutical combinations including compositions and kits comprising bretylium as the active ingredient, as well as methods for preventing and / or treating conditions related to the cardiovascular system using such novel pharmaceutical combinations.

A means and method for treating malaria, schistosomiasis, and cancer using a spiro or dispiro 1,2,4-trioxolane is described. The preferred 1,2,4-trioxolanes include a spiroadamantane group on one side of the trioxolane group, and a spirocyclohexyl on the other side of the trioxolane group. In comparison to artemisinin semisynthetic derivatives, the compounds of this invention are structurally simple, easy to synthesize, non-toxic, and potent against malarial parasites. The compounds of the invention unexpectedly provide a single-dose cure for malaria, as well as prophylactic activity against the same. The compounds are also active against schistosomiasis and cancer.

An embodiment of the present invention relates to a compound of the general formula. The compound of formula is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Furthermore an embodiment of the present invention concerns a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.